EVE-M® (Enhancing the vaginal environment and microbiome)

Harness the health promoting properties of a small molecule produced by an optimal vaginal microbiome to combat a variety of conditions affecting women’s sexual and reproductive health including HIV and other STIs, spontaneous preterm birth, infertility, and endometritis.

Ongoing

The small molecule will be formulated in a variety of ways for delivery into the vagina. Formulations will be tested in preclinical studies, mechanistic studies in women, and clinical efficacy studies.

Women’s sexual and reproductive health is often neglected with little progress in BV treatment in the past 25 years despite its economic and associated health impact. The estimated annual global economic burden of treating BV symptomatic BV is $USD 4.8 billion.  BV is the most common vaginal syndrome affecting women of reproductive age.  Both symptomatic and asymptomatic BV is associated with adverse health outcomes. BV is estimated to affect 20-30% of indigenous Australian women and women in Papua New Guinea.  Of the 1.5 million new HIV infections in 2021, 49% were in women with the majority of these infections occurring in adolescent girls and young women in sub-Saharan Africa where BV is highly prevalent. A non-optimal vaginal microbiome is associated with spontaneous  preterm birth. Preterm birth affects >15 million babies a year and is one of the leading causes of death of children <5 years. Symptomatic BV in women is also associated with adverse social and psychological consequences.